Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
1. A composition comprising, as an active ingredient, an iduronate-2-sulfatase (IDS) having the amino acid sequence of SEQ ID NO: 1, wherein a cysteine residue at position 59 in the IDS amino acid sequence is converted into formylglycine (FGly) at a molar ratio of 65% or higher.
2. The composition of claim 1 , wherein the cysteine residue at position 59 in the IDS amino acid sequence is converted into FGly at a molar ratio of 75% or higher.
3. The composition of claim 1 , wherein the IDS contains mannose-6-phosphate in an amount of 2.0 to 4.0 moles per mole of IDS.
4. The composition of claim 3 , wherein the IDS contains mannose-6-phosphate in an amount of 2.5 to 3.0 moles per mole of IDS.
5. A formulation comprising the composition of claim 1 .
6. The formulation of claim 5 , further comprising:
a pharmaceutically acceptable carrier; and
a substance selected from the group consisting of a buffer, a carbohydrate, a stabilizer, an antioxidant, a bacteriostatics, a chelating agent, an adjuvant, a suspending agent, a thickener, and a preservative.
7. A method for preparing the composition of claim 1 , comprising:
(1) culturing a recombinant host cell strain transformed with a gene encoding IDS comprising the amino acid sequence of SEQ ID NO: 1 and obtaining the culture; and
(2) purifying the IDS from the culture through anion exchange chromatography, hydrophobic chromatography, cation exchange chromatography, and affinity chromatography to obtain the composition.
8. A method for preparing the composition of claim 1 , comprising:
(1) transforming a host cell with an expression vector carrying an IDS gene to obtain a recombinant cell strain;
(2) culturing the recombinant cell strain in the presence of a hydrolysate in a serum-free medium and obtaining the culture;
(3) purifying the IDS from the culture through anion exchange chromatography, hydrophobic chromatography, cation exchange chromatography and affinity chromatography; and
(4) combining the purified IDS with a pharmaceutically acceptable carrier to obtain the composition.
9. The method of claim 7 , wherein the host cell is a Chinese hamster ovary cell.
10. The method of claim 7 , wherein the cation exchange chromatography is performed using an elution buffer with a pH of 4.0 to 6.0.
11. The method of claim 7 , wherein the hydrophobic chromatography is performed using an elution buffer with a pH of 5.0 to 7.0.
12. The method of claim 7 , wherein the affinity chromatography is performed using an elution buffer with a pH of 6.0 to 8.0.
13. The method of claim 7 , wherein the anion exchange chromatography is performed using an elution buffer with a pH of 5.5 to 7.5.
14. The method of claim 7 , further comprising inactivating viruses at a pH of 3.0 to 4.0.
15. A method for preparing a formulation for treating Hunter syndrome, comprising formulating the composition prepared according to the method of claim 7 .
16. The method of claim 8 , wherein the host cell is a Chinese hamster ovary cell.
17. The method of claim 8 , wherein the cation exchange chromatography is performed using an elution buffer with a pH of 4.0 to 6.0.
18. The method of claim 8 , wherein the hydrophobic chromatography is performed using an elution buffer with a pH of 5.0 to 7.0.
19. The method of claim 8 , wherein the affinity chromatography is performed using an elution buffer with a pH of 6.0 to 8.0.
20. The method of claim 8 , wherein the anion exchange chromatography is performed using an elution buffer with a pH of 5.5 to 7.5.
21. The method of claim 8 , further comprising inactivating viruses at a pH of 3.0 to 4.0.
22. The formulation of claim 5 , wherein the cysteine residue at position 59 in the IDS amino acid sequence is converted into FGly at a molar ratio of 75% or higher.
23. The formulation of claim 5 , wherein the IDS contains mannose-6-phosphate in an amount of 2.0 to 4.0 moles per mole of IDS.
24. The formulation of claim 23 , wherein the IDS contains mannose-6-phosphate in an amount of 2.5 to 3.0 moles per mole of IDS.